Group 1 - The company MicroPort Robotics-B (02252) reported that as of the announcement date, the cumulative order volume for its core products in endoscopy, orthopedics, and vascular intervention exceeded 130 units [1] - The Tumi endoscopic surgical robot has achieved over 70 cumulative commercial orders globally, with nearly 20 new commercial orders signed in 2025, and the total installed base has surpassed 50 units [1] - Tumi has accelerated its clinical application, with over 10,000 human clinical surgeries performed globally to date [1] Group 2 - As of 2025, Tumi has received registration certification in over 10 countries or regions, with a total of more than 30 certified countries or regions worldwide [1] - The Tumi robot's clinical effectiveness, stability, safety, innovation level, and technological content have been increasingly recognized by international regulatory authorities [1] - The Honghu orthopedic surgical robot received registration approval from Health Canada in January 2025, expanding its presence in the global orthopedic surgical robot market [1] Group 3 - Following the global first registration approval for Tumi's remote surgery application in April 2025, the company continues to explore clinical applications in this field [2] - Tumi recently assisted Belgian surgeons in completing two remote surgeries, marking the first robot-assisted remote human surgeries in Europe [2] - The surgeries utilized a hospital's conventional network (V-LAN) with a bidirectional delay of only 20 milliseconds, ensuring the precision required for remote robotic surgery [2]

Financial Data and Key Metrics Changes - The company reported robust organic sales growth of 10.1% in Q1 2025, with adjusted EPS of $2.84, reflecting a 13.6% increase compared to Q1 2024 [5][6][16] - The adjusted gross margin improved to 65.5%, up 190 basis points year-over-year, while the adjusted operating margin was 22.9%, an increase of 100 basis points [23][27] - The company anticipates full-year organic sales growth of 8.5% to 9.5% and adjusted EPS in the range of $13.2 to $13.45 [7][26][27] Business Line Data and Key Metrics Changes - MedSurg and Neurotechnology achieved organic sales growth of 10.7%, with U.S. growth at 11.4% and international growth at 8.2% [16][19] - The Instruments segment saw U.S. organic sales growth of 10.4%, while Endoscopy reported 11.1% growth driven by core portfolios [17][18] - Orthopedics had organic sales growth of 9.3%, with U.S. knee business growing 8.3% and trauma and extremities growing 15.2% [19][20][21] Market Data and Key Metrics Changes - U.S. organic sales growth was 10.7%, while international organic sales growth was 8.5%, with notable strength in Australia, New Zealand, Japan, and Europe [15][19] - The company noted a favorable pricing impact of 0.7%, while foreign currency had a 0.9% unfavorable impact on sales [14][15] Company Strategy and Development Direction - The company completed the acquisition of Inari Medical, with integration going well and expected to contribute positively to the vascular division [7][12][50] - The company continues to focus on innovation and product launches, including the Mako robotic system and the Pangaea plating system, which are expected to drive future growth [10][11][12][58] - The company is addressing tariff impacts through pricing strategies, operational efficiencies, and leveraging its manufacturing footprint [27][33][68] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the sustainability of growth, citing strong demand and no significant red flags in the operating environment [35][40] - Supply chain disruptions were acknowledged, particularly in the medical segment, but these were factored into the guidance [40] - The company remains optimistic about maintaining strong sales momentum and achieving its margin improvement targets despite tariff challenges [27][44][68] Other Important Information - The company has been recognized for the fifteenth consecutive year on Great Place to Work's list of 100 Best Companies to Work For, highlighting its strong corporate culture [8] - The company expects a tariff impact of approximately $200 million in 2025, with ongoing efforts to mitigate this through various strategies [27][33] Q&A Session Summary Question: How is the company planning to absorb the estimated $200 million tariff impact? - Management indicated that the absorption will come from strong sales momentum, pricing strategies, and optimizing operational expenditures [30][32] Question: What is the outlook for the orthopedics market and the company's positioning? - Management noted that the orthopedics market remains healthy, with expectations for growth above the market average due to strong demand and successful product launches [34][35] Question: Can you provide insights on the gross margin expectations for the rest of the year? - Management expects a balanced contribution to margin improvement from both gross margin and operational expenditures, despite potential tariff impacts in the latter half of the year [42][44] Question: How is the integration of Inari progressing? - The integration is going well, with positive early performance and alignment with the company's culture [50] Question: What are the expectations for capital expenditures in 2026? - Management indicated that it is too early to provide a detailed outlook for 2026, but they remain optimistic about capital needs tied to strong procedural volumes [102]

MedRobot 近日 直观医疗I ntui tive （纳斯达克股票代码： ISRG )频繁被分析师提及——收购经销商、关税问 题的影响等等。 尽管面临供应链挑战， 直观医疗Intuitive（纳斯达克股票代码： ISRG )的新一代手术机器人系统达芬奇5在 2024年取得了显著的成绩。根据公司年度财报数据显示，自2024年3月推出以来，全球共安装了362台达芬奇5 系统，其中174台在第四季度完成安装。全年共有超过2500名外科医生使用该系统完成了32000多例手术，充分 体现了机器人辅助手术的强劲需求。 装机量破万！收入612亿！达芬奇最新财报！ 直观医疗 首席执行官Gary Guthart近日在电话会议上透露了更多信息： # 回顾2024年 全面推出达芬奇5（2024年是针对部分老客户限量销售）；（MedRobot备注：这似乎是在说，既 然关税导致成本压力大，那就努力卖价格更高的达芬奇5） 达芬奇5：价格上涨30%，更多细节见内 ； 最新！达芬奇5数据应用方向大揭秘 顶级设计！直击达芬奇5代机器人新亮点 在美国、德国、保加利亚增加工厂； 开展直销、 增强培训等 等。 收购经销商！达芬奇撸起袖子自己干 ...